The European Medicines Agency is preparing for a future without the UK, by distributing the country’s existing workload among the other EU member states.
The EMA is operating on the assumption that the UK will no longer participate in its work as of 30 March 2019, the agency said in a press release last week. This is despite the fact that the future relationship between the UK and the EMA has not yet been settled by negotiators.
The work of the UK’s Medicines and Healthcare products Regulatory Agency (MHRA) is closely tied up with that of the EMA, which has been based in London since it was established in 1995. That close relationship is being jeopardised by the UK’s exit from the EU, which is likely to force the EMA to relocate to another EU country and remove the UK from its jurisdiction.